These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21945232)

  • 1. MP's and VTE's: Fact or fiction.
    Owens AP; Mackman N
    Thromb Res; 2011 Dec; 128(6):505-6. PubMed ID: 21945232
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.
    Campello E; Spiezia L; Radu CM; Bulato C; Castelli M; Gavasso S; Simioni P
    Thromb Res; 2011 May; 127(5):473-7. PubMed ID: 21256535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticles: new light shed on the understanding of venous thromboembolism.
    Zhou L; Qi XL; Xu MX; Mao Y; Liu ML; Song HM
    Acta Pharmacol Sin; 2014 Sep; 35(9):1103-10. PubMed ID: 25152025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of matters great and small.
    Versteeg HH; Rodger M
    Thromb Res; 2017 Feb; 150():101. PubMed ID: 28137540
    [No Abstract]   [Full Text] [Related]  

  • 5. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?
    Tushuizen ME; Diamant M; Sturk A; Nieuwland R
    Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):4-9. PubMed ID: 21160062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microparticles: an introduction.
    Boulanger CM; Dignat-George F
    Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):2-3. PubMed ID: 21160061
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanistic view of risk factors for venous thromboembolism.
    Reitsma PH; Versteeg HH; Middeldorp S
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):563-8. PubMed ID: 22345594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients." reply to a comment by Geddings and Mackman.
    Hernández C; Roncal C; Orbe J; Páramo JA
    Thromb Haemost; 2014 Jan; 111(1):182. PubMed ID: 24154596
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating procoagulant microparticles in patients with venous thromboembolism.
    Ay C; Freyssinet JM; Sailer T; Vormittag R; Pabinger I
    Thromb Res; 2009 Mar; 123(5):724-6. PubMed ID: 18995886
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on "tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients".
    Geddings JE; Mackman N
    Thromb Haemost; 2014 Jan; 111(1):180-1. PubMed ID: 24153434
    [No Abstract]   [Full Text] [Related]  

  • 11. Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation.
    Eleftheriou D; Hong Y; Klein NJ; Brogan PA
    J Thromb Haemost; 2011 Sep; 9(9):1864-7. PubMed ID: 21733119
    [No Abstract]   [Full Text] [Related]  

  • 12. Microparticles and pregnancy complications.
    Aharon A; Brenner B
    Thromb Res; 2011 Feb; 127 Suppl 3():S67-71. PubMed ID: 21262446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma microparticles are not elevated in fresh plasma from patients with gynaecological malignancy--an observational study.
    Zahra S; Anderson JA; Stirling D; Ludlam CA
    Gynecol Oncol; 2011 Oct; 123(1):152-6. PubMed ID: 21777967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The many faces of endothelial microparticles.
    Dignat-George F; Boulanger CM
    Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):27-33. PubMed ID: 21160065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating procoagulant microparticles in cancer patients.
    Thaler J; Ay C; Weinstabl H; Dunkler D; Simanek R; Vormittag R; Freyssinet JM; Zielinski C; Pabinger I
    Ann Hematol; 2011 Apr; 90(4):447-53. PubMed ID: 20981426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-derived microparticles in haemostasis and vascular medicine.
    Burnier L; Fontana P; Kwak BR; Angelillo-Scherrer A
    Thromb Haemost; 2009 Mar; 101(3):439-51. PubMed ID: 19277403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic markers of neurologic diseases: the control groups.
    Cohen AB
    Ann Neurol; 2010 Mar; 67(3):409; author reply 409. PubMed ID: 20373356
    [No Abstract]   [Full Text] [Related]  

  • 18. Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: a clinical analysis.
    Wu Q; Chen H; Fang J; Xie W; Hong M; Xia L
    Leuk Res; 2012 Mar; 36(3):275-80. PubMed ID: 21917312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress.
    Helal O; Defoort C; Robert S; Marin C; Lesavre N; Lopez-Miranda J; Risérus U; Basu S; Lovegrove J; McMonagle J; Roche HM; Dignat-George F; Lairon D
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):665-71. PubMed ID: 20399083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib.
    Connor DE; Exner T; Ma DD; Joseph JE
    Thromb Haemost; 2010 May; 103(5):1044-52. PubMed ID: 20390225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.